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Objective/purpose
CD34 is a cell surface sialomucin that has been the sub-
ject of extensive interest, largely based on its use as a
marker for hematopoietic stem cells (HSCs) and vascu-
lar endothelia. Despite the almost ubiquitous use of
CD34 as a HSC marker, little is known about its cellular
function. Our lab was the first to show that CD34 is
also highly expressed on mature murine mast cells, and
w ea n do t h e rg r o u p sh a v ef o u n di tt ob ee x p r e s s e do n
eosinophils and dendritic cells. We found that mast cells
derived from Cd34
-/- mice exhibit a marked increase in
cell-cell aggregation. Moreover, when Cd34
-/- mice were
challenged in a mouse model of asthma, immune cell
accumulation in the lung was drastically reduced, while
the number of immune cells in the lung at baseline was
similar to that of their wild-type counterparts. We have
since found that deletion of the Cd34 gene in mice ren-
ders these animals resistant to a wide range of other
mucosal inflammatory diseases, including hypersensitiv-
ity pneumonitis (HP), ulcerative colitis, salmonella infec-
tion and intestinal tumor development. Our objectives
are to examine the specific role of CD34 in cellular
function and to see whether or not CD34 is a viable
therapeutic target to treat mucosal inflammatory
diseases.
Methods
Bone marrow mast cells were derived from wild-type
and Cd34
-/- mice after four week culture in media con-
taining IL-3. Changes in migration, polarization, degra-
nulation and cytokine production were measured after
c-kit and/or FceRI stimulation. For in vivo studies, we
developed transgenic mice that lack the mouse Cd34
gene and instead express, in all the appropriate tissues,
the human Cd34 gene. These mice were put through a
standard Ovalbumin (OVA) induced asthma model. Air-
way inflammation severity was assessed by analysis of
the broncho-alveolar lavage (BAL) content, histological
scoring of H&E stained lung sections and cytokine pro-
duction of isolated lung inflammatory cells in response
to OVA.
Findings
Preliminary experiments have suggested that CD34 plays
an important role in c-kit signaling events and FceRI
induced degranulation. Initial testing of our hCd34
tg
mice has shown that expression of the human Cd34
gene in CD34-deficient mice is sufficient to regain sus-
ceptibility to both allergic asthma and HP in mouse
CD34-deficient animals. These findings suggest that
human CD34 serves a similar function to mouse CD34
in both animal disease models.
Deliverables and relevance
We show that in mast cells, CD34 plays an important
role in regulating cellular signaling through both the c-
kit and FceRI pathways. In addition, we have demon-
strated that expression of human CD34 serves a similar
function to mouse CD34 in both asthma and HP, pro-
viding a proof-of-concept to assess therapeutics target-
ing human CD34 in hCd34
tg mice as a humanized
mouse model to treat these diseases. Allergic asthma
affects more than 10% of all North Americans and is a
major cause of hospitalization of children. Current ther-
apeutics are largely ineffective for chronic asthma and
the most potent therapies can carry a number of side
effects. CD34 could represent a new therapeutic target,
and since we have shown that CD34 plays a role in the
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© 2010 Gold et al; licensee BioMed Central Ltd.susceptibility to a wide range of mucosal inflammatory
diseases, it is likely that it could serve as a viable treat-
ment for a number of diseases.
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